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Risk/benefits of oral retinoids 
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Panel discussion: 
patients receiving 
long-term basis 
Benefit/risk judgments for 
retinoids on a short- and 
G. D. Weinstein, M.D.: In the last decade many of 
us have wrestled with the problem of defining benefit/ 
risk judgments for new therapies in dermatology, par- 
ticularly psoriasis and specifically on the use of metho- 
trexate and PUVA. At this meeting we have seen the 
situation in which we have both efficacy and toxicity of 
a drug, and we have to consider the problem: "What 
are the benefit/risk judgments going to be for patients 
who will be eligible to receive retinoids for the various 
diseases?" This is not an easy problem, as I am sure 
you all realize. One of the big difficulties is that there 
are many variables that come into play. For some pa- 
tients, such as those with cystic ache, we are talking 
about short-term therapy. For patients with diseases 
such as psoriasis or ichthyosis, it is long-term therapy. 
We have problems related to age, sex, diagnosis, and 
which retinoid is being used. We have asked this panel, 
all of whom have used retinoids in various ways, to 
start with a statement concerning the benefit/risk judg- 
ment and then we will open the subject o all the par- 
ticipants. 
H. H. Roenigk, Jr . ,  M.D.: Let me just address one 
aspect of the problem, namely, the potential liver tox- 
icity. I do not think this is necessarily the most serious 
problem, especially in dealing with psoriasis. I think 
that teratogenicity is probably a much more serious 
problem. But I think that when you try to compare the 
potential liver toxicity of etretinate with alternative 
choices that we have, the risk/benefit s probably in the 
middle. The three major types of systemic therapy 
which are generally available today for psoriasis are 
retinoids, PUVA, and methotrexate. Of these, metho- 
trexate probably has much greater potential of produc- 
ing serious damage to the liver. PUVA probably has no 
effect whatsoever on the liver, and the retinoids, I would 
say, probably fall somewhere in the middle. While vi- 
tamin A does have an effect on the liver, it was initially 
thought hat the synthetic retinoids were not going to 
have a similar effect. However, I think that it is now 
partially clear that there is some storage in the liver. 
Our own studies presently indicate that liver damage is 
potentially minimal, but the data are still very prelimi- 
nary. The fact that i took us 20 years to learn about he 
liver toxicity of methotrexate, and we still do not know 
the final answer to this problem, indicates the need for 
continuous monitoring. The point is that while it may 
not take that long, it may be 10 years before we know 
whether etretinate produces significant liver toxicity. 
However, I do not think that this is a reason to withhold 
therapy from patients. 
L. C. Harber, M.D.: I would like to broaden the 
remarks of Dr. Roenigk a bit if I may to say that I think 
the whole concept of a risk[benefit ratio represents our 
profession at its best or at its worst, It doesn't involve a 
drug, it involves a one-to-one relationship between a
physician at a given time and a patient at a given time 
and the dialogue that they enter into. Some of the risk 
factors would make me give different answers to differ- 
ent people at different imes. The keystone of any type 
of dialogue between a physician and a patient is the 
firm body of scientific knowledge. As it applies to the 
retinoids, I have no hesitancy, in view of all the toxicity 
studies which have been discussed today, to actively 
give the medication to people with the type of cystic 
acne that was shown. I would have no hesitancy in 
giving it to the rapid proliferative conditions that were 
shown by several of the people. On the other hand, 
there are milder forms of psoriasis, or even some of the 
forms that were shown today, that I would have reser- 
vations on. Now, that is only in terms of the disease. 
After that, when we talk about people at risk where we 
do not know the period of time that the risk will per- 
petuate itself, I think it calls for some very serious 
thinking and I have no glib answers. 
L. A. Goldsmith, M,D.: I guess the question is, 
"What would I do if I had an unlimited supply of oral 
retinoids?" My own experience has been with isotreti- 
noin, and [ will talk about hat. I f I  were to use the drug 
for short-term patients with cystic acne and use it to see 
if one can put a patient with pityriasis rubra pilaris into 
remission, I could feel good about using the drug, for 
we already know that there is tremendous potential gain 
and we have data that the risk is very low. This repre- 
sents an approach to one group of patients. 
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The second group of patients are those with Darier's 
disease and the various forms of ichthyosis who are 
really severely limited by their disease in terms of what 
they can do in school, what they can do in their life, 
and in their whole outlook to the world. They represent 
a very challenging roup. In general, I put these pa- 
tients on oral retinoids, especially if they have had var- 
ious other forms of therapy without good results. How- 
ever, I am very concerned when I hear about patients 
with ichthyosis vulgaris and X-linked ichthyosis who 
are on oral retinoids. At least from my personal point of
view, we can treat these two much more common dis- 
eases with absolutely benign kinds of therapies with 
which one really does not worry about risks. I am very 
concerned about the question of teratogenicity with 
etretinate. That is a potential time bomb. It will take time 
for all of us to learn how to use the retinoids. It has 
taken us a long time to learn how to use steroids. I do 
not think that we should feel that we know how to use 
retinoids perfectly, since we have only had them for a 
short time. I think that we already have a good idea 
about dose ranges. I am concerned that we have had to 
wait a long time to find out about the pharmacokinetics 
of this drug. I think that, since there are going to be 
second and third generation retinoids coming along, it 
is going to be really critical to have the pharmacoki- 
netic data very early in the game in the future. 
T. P. Nigra, M.D.: In December of 1978, when we 
first found that seven of our ten patients had triglyceride 
elevations, I thought that this elevation might be the 
death knell of isotretinoin as a drug. But I really think 
that I have changed my mind a lot on this issue. I think 
that the triglyceride levation is something that in cer- 
tain situations we can live with. For instance, if you are 
going to use the drug only for short periods of time, 
such as in cystic acne, then I think that one can live 
with some triglyceride levation. Nevertheless, hort- 
term elevation can result in acute pancreatitis and erup- 
tive xanthomas. 
However, there comes the problem of long-term use 
of the drug and long-term triglyceride levation. Here 
there is a change in the risk/benefit ratio. In our situa- 
tion, we elected to discontinue the drug on one 50- 
year-old man who had elevations of both the triglycer- 
ides and the cholesterol. We had another 13-year-old 
boy with Darier's disease, whose data were presented 
by Dr. Windhorst, in whom we continued the drug. His 
father had died of a heart attack at the age of 37. When 
we drew his baseline studies, the boy had type 4 hyper- 
lipoproteinemia. Diet definitely helps his hyperlipopro- 
teinemia, and when he is on his diet his baseline lipid 
values are within normal limits. When we give him the 
drug, his lipid levels go up. However, since we have to 
give him isotretinoin for only 1 week out of every 3 
months, we feel that we are adequately dealing with the 
risk/benefit problem. 
When it comes to the problem of teratogenicity, I 
would like to discuss another patient. We are treating a
young lady who has pustular psoriasis of her hands. 
Her fingers are atrophied as a result of topical steroid 
therapy. She has used PUVA to the point of neurotox- 
icity or phototoxicity, methotrexate o the point of ul- 
cers in her mouth, vitamin A to the point of pseudotu- 
mot, and the steroids to the point of atrophy. Nothing 
has worked for her. She is obviously psychologically 
disabled by her disease. A long time ago I was very 
anxious to use etretinate on her. But now that teratogen- 
icity has really become obvious, I really think that the 
risk/benefit ratio s a problem, and even with all of 
those modalities not working, I would still not use etret- 
inate. Unfortunately, I think she has got to live with her 
disease. 
J. S. Strauss, M.D.: It is interesting to me that there 
is so much concern about the side effects among those 
at this conference. This is a healthy situation because 
we who have had an opportunity to use the drug will 
have to provide continuing uidance when the drug is 
initially marketed. Dr. Harber has said we need to look 
at the risk/benefit ratio very seriously in every patient. 
These drugs are not, at this point, the treatment of 
choice for every case of cystic acne or psoriasis. In the 
management of acne, we are probably in a better posi- 
tion with regard to safety since the current data indicate 
that smaller dosages can probably be used in the major- 
ity of cases requiring retinoid therapy. Furthermore, the 
course of therapy may be relatively short and remis- 
sions may be prolonged. However, I am not sure that 
we have established the optimal dosage. Another ad- 
vantage that we have is that we are using isotretinoin 
and not etretinate, since animal studies have shown that 
the former is less teratogenic. The retinoids, like other 
drugs or modalities uch as methotrexate or PUVA, 
have their proper place in the management of otherwise 
treatment-resistant dermatologic diseases. Careful de- 
cisions as to the appropriateness of therapy will have to 
be made for each patient. If we maintain this attitude 
and also continue to carefully monitor new retinoids as 
they are developed, these drugs should be of great aid 
in clinical practice. 
J. H. Epstein, M.D.: At present here is little in- 
formation on the effects of systemic retinoids on pho- 
tocarcinogenesis. However, we are in the process of 
examining the effects of oral isotretinoin in our hairless 
mouse system with the use of a hot quartz ultraviolet 
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light source. The mice are irradiated three times a week 
and receive 10 mg/kg of isotretinoin orally five times a 
week. The development of tumors greater than 4, 50, 
and 100 mm 3 has followed essentially the same patterns 
to date as expressed in Table I. As noted, by 34 weeks 
no significant effect of the chemical has been detected 
under the circumstances of this study. 
Be that as it may, it has been established that treti- 
noin can both accelerate and inhibit photocarcinogenesis 
under appropriate conditions. The mechanism or mech- 
anisms involved in either effect are not clear. 
Stimulation of UV carcinogenesis might be related 
to effects on DNA metabolism and induction of epi- 
dermal proliferation, or immunosuppression which has 
been demonstrated with high doses of tretinoin. Unfor- 
tunately, there are very few data available at this time 
which might explain this demonstrated accelerating ef- 
fect of tretinoin on photocarcinogenesis. 
In contrast, there are a number of studies describing 
tretinoin effects which might be responsible for the in- 
hibitory response noted. In a recent study we noted that 
though repeated applications of tretinoin over a 10- and 
23-week period caused epidermal acanthosis, they 
blunted the response of the skin to acute UV injury. 
Thus the expected increase in DNA synthesis and hy- 
perplastic response which occurs by 24 hours post UV 
irradiation was significantly suppressed. 
I would suggest hat if anyone does have a patient 
with xeroderma pigmentosum, this would be an excel- 
lent type of patient in whom the problem of UV car- 
cinogenesis could be investigated. Of course, Dr. Peck 
has experience with the basal cell nevus syndrome and 
the multiple basal cell cancers. His studies look en- 
couraging at/east at this point. 
G, G. Krueger, M.D.: I keep coming back to the 
question of how we should deal with our institutional 
review boards. Neither we nor the review boards know 
how to interpret the animal data, such as the data per- 
taining to adrenal tumors. I am wondering, Dr. Wind- 
horst, if you could, for just a few minutes, try to take it 
from our point of view and tell us what we should say 
to an institutional review board. 
D. B. Windhorst, M.D.: In the absence of a 
definitive reason to feel some special risk has come up 
requiring a study to be stopped, it is the monitor's 
responsibility to keep the investigator fully informed 
about all data that become available on the drug under 
study. The observation of pheochromocytomas in the 
chronic rat study is just as confusing and disturbing to 
me, raising all kinds of scientific and ethical questions, 
as it is to you. There is no clear way to interpret the data 
for applicability to humans who are being dosed in 
Table I .  Percent of mice with tumors greater 
than 50 mm ~ at the noted t ime periods 
No. of weeks .I Is°tretin.°in (%)* I Control (%) 
24 9 13 
29 13 23 
34 42 39 
*These mice received 10 mg/kg of isotretinoin orally 5 days a week. 
significantly different ways. My job is to keep you 
informed. However, the ultimate answer elates to your 
individual patient, and only you have the maximum 
information available regarding the benefit the patient 
is obtaining from the drug. As hard as it sounds, I think 
that when I play my role correctly and keep you in- 
formed, the ultimate risk/benefit judgments hould rest 
with you and your patient, with the help of your in- 
stitutional review committee. 
J. J. Voorhees, M.D.: I would like to say that in 
using etretinate for psoriasis, I have not seen any im- 
provement orany worsening in psoriatic arthritis, and if 
other people who have made such an observation could 
comment, it would be helpful for me. Also I want to 
return to Dr. Strauss' pivotal question about teratogen- 
esis; I either did not understand the answer or it was not 
clear to me. Dr. Strauss wanted to know whether the 
ovum in the ovary is going to be damaged such that if a 
woman becomes pregnant 5 years later teratogenesis 
might be a problem even then. I really did not get a 
crisp answer to that question. 
H. I-I. Roenigk, J r . ,  M.D.: I will respond to the 
arthritis question. Five out of our twenty patients had 
fairly severe arthritis. Most of them required other 
nonsteroidal, anti-inflammatory type drugs during the 
initial phases of retinoid therapy. Four out of the five 
were able to discontinue all of their anti-inflammatory 
drugs during retinoid therapy, There was significant 
objective and subjective improvement in arthritis. A 
number of the patients have come off the drug for a 
3-month rest period, and at least two of the five have 
now had a flare of their arthritis while they were off 
retinoid therapy. 
W. D. Stewart, M.D.: We have had a similar ex- 
perience to Dr. Roenigk's. Six of our patients had 
psoriatic arthritis; all of them had been treated previ- 
ously with antiarthritic medications. They have been 
treated with etretinate in a dosage level of either 25 or 
50 rag/day (mostly 25 mg/day). One other point is that 
the onset of the disease is relatively recent in these 
patients, and they all have inflammatory types of ar- 
thritis. These are not patients with long-term, chronic, 
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deforming arthritis. All of the patients have responded 
quite satisfactorily and significantly to retinoid therapy. 
G. Plewig, M.D.: We have had the same experi- 
ence. Arthritis does improve in many patients. I also 
feel that the yon Zumbusch pustular type of psoriasis, 
as well as pustular psoriasis of the Hallopeau type and 
the palmar-plantaris type, shows excellent improve- 
ment. The dose required for all these forms of pustular 
psoriasis is lower than for the chronic, stationary type. 
If I might change the subject, together with Profes- 
sor Schill from our department we have looked into 
sperm parameters in patients with conglobate acne. 
Almost every single patient with conglobate acne had 
an abnormal finding in one or several of the seven 
parameters in the sperm samples that were examined 
prior to therapy. These abnormalities all improved and 
came back to normal while the patients were being 
treated with isotretinoin. Severe inflammatory skin dis- 
ease, such as Darier's disease and severe acne, can 
affect sperm production; this can apparently be cor- 
rected by treating the basic disease. 
G. D. Weinstein, M.D.: Dr. Kamm, can you han- 
dle the teratogenicity situation. 
J .  J .  Kamm,  Ph.D.: The types of testing that we do 
would not directly address the question of fertilization 
of a "retinoid-damaged ovum" 5 years after stopping 
treatment. I do not think that irreversible damage to the 
ova in a woman can lead to teratogenesis because it 
seems to me that a damaged germ cell would not be 
fertilized or, if fertilized, would not implant. Under 
these circumstances, there would be no teratogenesis. 
However, if there were damage to the ova, this could 
certainly lead to decreased fertility. 
G. D. Weinstein, M.D.: Didn't you say you had 
some data, though, in the animals receiving the drug 
prior to conception? 
J. J. Kamm,  Ph.D.:  You are referring to a 
segment-I, reproduction/fertility study. In this type of 
study, treatment of the female is not stopped at the time 
of mating. Treatment is initiated 14 days prior to mat- 
ing and is continued through parturition. There is no 
cessation of treatment. 
G. D. Weinstein, M.D.: So we do not have any 
clean study in which the animals are treated prior to 
conception and then treatment is stopped. 
J. J .  Kamm,  Ph.D.: The model which would have 
to be studied is one in which animals are mated at 
varying times after treatment had stopped. We have not 
done studies of this type. 
J .  S. Strauss, M.D.: Did you dose both the males 
and females together? 
J. J. Kamm,  Ph.D.: Yes. In the segment-I study, 
both males and females were treated. 
J. S. Strauss, M.D.: So you do not have informa- 
tion based on administration of the retinoids, to females 
only before mating, 
J. J. Kamm, Ph.D.: With respect o 13-cis-retinoic 
acid, there were no adverse ffects on fertility or repro- 
ductive performance at the doses studied. Since there 
was no suggestion of any adverse ffect, there was no 
need to determine whether males or females or both had 
been affected. If there had been adverse ffects, then it 
would be a simple matter to treat males, mate them 
with normal females, and vice versa. The question hav- 
ing to do with irreversible ffects on ova which are 
elaborated long after treatment has stopped is not ad- 
dressed in any of the reproduction studies that we nor- 
mally do in our laboratory. 
D. B. Windhorst, M.D.: It is important o re- 
member that isotretinoin is not mutagenic in the bacte- 
rial system. 
L. A. Goldsmith, M.D.: Since it appears that some 
of the metabolites of etretinate could be very active, 
unless the bacterial system is set up for a conversion to 
all of its distal products, a negative study might not 
give you a true answer. 
J. J. Kamm,  Ph.D.: That is very true. However, 
the Ames test is designed to address the question of 
mutagenic metabolites. This is done by including in the 
assay system the so-called $9 fraction from liver which 
contains the drug-metabolizing enzyme system. The 
drug is preincubated with the liver $9 fraction, and the 
mixture, which contains unchanged rug and metabo- 
lites, is assayed for mutagenic potential. It can be ar- 
gued that we are using $9 or drug-metabolizing system 
from a rat and we know that there are species, strain, 
and sex differences in rates of metabolism as well as in 
routes of metabolism. However, it is purely academic 
at this point since we have done carcinogenicity studies 
in rodents with both 13-cis-retinoic acid and etretinate. 
A. R. Shalita, M.D.: I think the question with re- 
gard to the gametes really relates to whether or not 
there is any evidence of chromosomal damage. Any 
other effect on the ovum or on the spermatazoa would 
not lead to fertilization. Chromosomal damage, though, 
could lead to an abnormal fetus. Are there any data that 
chromosomal breaks or damage or anything like that 
occurs in animal models? 
J. J. Kamm,  Ph.D.: Studies with etretinate have 
been negative in terms of chromosome damage. I am 
not aware that they have been done with 13-cis-retinoic 
acid. 
G. L. Peek, M.D.: Dr. Kamm, one critical question 
is, "At what point in time is it safe for a woman who 
has received etretinate to have a child?" Are there stud- 
ies, for instance, in which animals that have been 
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treated for prolonged periods with etretinate have devel- 
oped large tissue stores, and then have become pregnant 
at varying periods of time after stopping therapy?" 
J .  J. Kamm, Ph.D.: A protocol has been developed 
to specifically address that question in animal models. 
The experiment is in its planning stages now, and we 
intend to correlate, or try to correlate, teratogenicity 
with blood levels. By determining blood levels at vari- 
ous times after stopping treatment and initiating mating 
at that same time, we hope to answer the question that 
you are asking. 
I believe that etretinate has been detected in the 
blood of patients for at least 6 months after stopping 
treatment. We do not know if this blood level would 
be associated with teratogenesis in animals. That is 
why it is a particular problem with etretinate but not 
with 13-cis-retinoic acid. With the latter you can tell 
the patient o wait 3 or 4 months after stopping medica- 
tion, by which time 13-cis-retinoic acid will have 
cleared her system. The problem with etretinate is its 
prolonged half-life. 
G. L. Peek, M.D.: One of the most difficult prob- 
lems we have in using retinoids is the management of 
retinoid-induced arthralgias. Some of the approximately 
5% of patients who develop arthralgias are disabled by 
this symptom and require high doses of anti-inflamma- 
tory agents, such as ibuprofen (Motrin) or indometha- 
cin (Indocin). In these cases, arthralgias become a 
dose-limiting toxicity. Our consultant rheumatologist 
once refused to let us enter a patient of hers with 
psoriasis and psoriatic arthritis into our etretinate pro- 
tocol for fear of aggravating the arthritis. The question 
then arises as to how the retinoids can induce arthral- 
gias in previously symptom-free patients and yet be 
effective in the treatment of psoriatic arthritis. 
G. Plewig, M.D.: We have seen four patients with 
acne fulminans accompanied by very painful arthral- 
gias. They were put on isotretinoin, and within 2 or 3 
weeks they lost their arthralgia complaints. Maybe reti- 
noids can be used in patients with other types of ar- 
thralgias. 
V. J. Derbes, M.D.: I should like to say that "ar- 
thralgia" is no more precise a term than is "head- 
ache." There are many mechanisms for joint pains as 
there are many mechanisms for head pain. I do not see 
any difficulty in observing a drug-producing pain in the 
one instance and relieving a type of pain in another 
instance. 
F. L. Meyskens, Jr., M.D.: I had a few comments 
that you might find helpful regarding the toxicity ques- 
tions that have been raised. Regarding chromosomal 
damage, extensive experience with many alkylating 
drugs in oncology generally indicates that unless you 
totally wipe out fertility in both males and females, 
normal children are produced subsequently. Secondly, 
regarding the liver toxicity, it is known that vitamin A 
produces fibrosis, which is a two-step rocess involv- 
ing two different ypes of collagen. It would be very 
useful to determine whether the reversible or the irre- 
versible type of collagen has been deposited in the liv- 
ers of the patients that Dr. Roenigk described (mono- 
clonal antibodies have now been developed for the five 
types of collagen). Thirdly, with regard to the pheo- 
chromocytoma nd adrenal medullary tumors, Dr. 
Krueger reminded me that most of my patients die in 
our cancer study, and we probably have postmortems 
on twenty or twenty-five patients; some of these pa- 
tients had received the drug for significant amounts of 
time. So one of the first things I want to do when I get 
back home is to look at the postmortems to see if there 
are any unexpected tumors present. 
D. B. Windhorst, M.D.: Just a comment on your 
plan to go back and do some examinations of your 
autopsy material: it would be useful to write down a set 
of possible observations and associated conclusions 
you might make before you look at the material because 
your patients probably had received multiple poten- 
tially toxic drugs. Unless you specify in advance what 
you might observe, and then say what that finding is 
going to mean to you, you can end up not knowing 
what to make of your data. 
C. N. Ellis, M.D.: We talked about combination 
therapy for psoriasis at length earlier. What combina- 
tion therapies have been used in Europe or elsewhere 
for the other disorders of keratinization? Wouldn't 
combinations be expected to l wer the risks of the reti- 
noid therapy? 
G. D. Weinstein, M.D.: Dr. Plewig, do you treat 
ichthyosis or Darier's disease with any combinations 
that include retinoids? 
G. Plewig, M.D.: I know of no controlled studies 
for ichthyosis or other disorders of keratinization in 
which two drugs were given systemically at the same 
time. Of course, topically we try various combinations 
like tar, anthralin, and ultraviolet light in combination 
with isotretinoin or etretinate. 
E. M. Farber, M.D.: I would like to ask the panel a 
question regarding the elevation of the blood triglycer- 
ides. Has anyone had experience in placing patients on 
a strict low animal fat diet and then resuming retinoid 
therapy. 
T. P. Nigra, M.D.: I have had experience in the 
~oung 13-year-old boy, as previously mentioned, We 
monitored him and when we felt he was not cheating, 
we found that his triglycerides were down, At that age 
it is difficult to stay on a diet, and many times his 
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triglycerides were elevated, which we believe was due 
to noncompliance. So, my impression is that diet would 
help a great deal in the use of this drug if one could 
obtain compliance. 
C. N. Ellis, M.D. The normal variability of tri- 
glycerides in patients must be kept in mind. During an 
8-week placebo period in nine of our psoriatic patients, 
six (67 %) had serum triglyceride levels which exceeded 
a single initial measurement by 20% or more. Of six 
patients with initially normal triglyceride levels, such 
variation during the placebo period resulted in two 
(33%) actually exceeding the upper limit of normal. 
These data indicate the necessity for adequate pre- 
therapy or placebo monitoring of patients. 
T. P. Nigra, M.D.: I might make another point, and 
that is that there are other drugs which do raise triglyc- 
erides. Systemic steroids and estrogens will do this. 
How often do we pause when we give someone sys- 
temic steroids to think about he triglyceride levation? 
J. S. Strauss, M.D.: I would like to go back to the 
question that Dr. Voorhees brought up relative to hor- 
monal action of the retinoids. I wonder whether poten- 
tial hormonal activity was looked at as part of the 
pharmacologic studies by Hoffmarm-La Roche. 
J. J. Kamm,  Ph.D.: We have not studied hormonal 
activity as part of our long-term toxicity studies. 
J, S. Strauss, M.D.: Have the oral retinoids been 
tested for androgenic, progestational, orestrogenic ac- 
tivity? 
J. J. Kamm,  Ph.D.: Not to my knowledge. 
D. S, Goodman,  M.D.:  Let me first comment about 
the hypertriglyceridemia as related to steroid hormone 
action. It is now well established that women on con- 
traceptive pills have, on average, higher lipid levels 
than women not on the pill. The main effect is due to 
the estrogen component of this contraceptive medica- 
tion. As I mentioned earlier, there is considerable un- 
certainty at the moment about the clinical significance 
of hypertriglyceridemia in the lipidology field. With 
regard to dietary treatment of elevated triglycerides 
(and exactly what one considers an elevated triglycer- 
ide level is now a little bit uncertain), the current gen- 
erally agreed upon thinking is that the most important 
variable is control of caloric intake, not of the distribu- 
tion of calories amongst foodstuffs. This is particularly 
true for obese, overweight people. And by overweight I 
don't only mean obviously obese people, because you 
can often find someone who is a little bit overweight, 
put them on a calorically restricted diet to lose ten 
pounds, and find a dramatic decrease from a triglycer- 
ide of about 300 mg/dl down to 200 or less. Moreover, 
there is a great heterogeneity among different people 
with regard to sensitivity of triglyceride level to caloric 
flux. So, the main element that is now felt to be impor- 
tant in regard to dietary treatment of hypertriglyceri- 
demia is control of calories. For this, you should use 
the same fat-controlled diet which is used for hyperlip- 
idemia in general, namely, a cholesterol-restricted in- 
take (less than 300 rag/day) and a fat intake of about 
35% of total calories with no more than 10% of calories 
as saturated fats. The old thought about restricting car- 
bohydrates for hypertriglyceridemia is definitely not 
now felt to be the proper approach. There are much 
data, in fact, that for the vast majority of patients car- 
bohydrate restriction is definitely not desirable. 
D. West, M.S.: Could Dr. Windhorst or perhaps 
Dr. Plewig or anyone else on the panel share with us 
the reported side effects attributable to the oral retinoids 
that we have not discussed to date. Perhaps there are 
none? 
G. Plewig, M.D.: One side effect of isotretinoin 
which has not been discussed here and which has 
caused some problems and dropouts in our studies is 
migrating arthralgia nd myalgia. All of a sudden pa- 
tients develop severe joint pain, usually of the big 
joints, shoulder, knee, or hip, or in the truncal muscles. 
It is not dose-related. We have seen it with the lowest 
dose of 0.1 mg/kg/day and also in the highest dose of 2 
mg/kg/day. It persists for days or weeks and seems to 
occur mainly in patients who do vigorous physical 
exercise. We had athletes and farmers who developed 
the symptoms. I have no explanation at present for this 
phenomenon, and I wonder if you have seen this symp- 
tom. This is with isotretinoin; we have not seen it with 
etretinate. 
D. B. Windhorst, M.D.: The data on all U.S. pa- 
tients who have received isotretinoin (grouping all 
musculoskeletal complaints together) indicate that ere 
is a 20% incidence of musculoskeletal complaints. 
J. G. Marks, J r . ,  M.D.: This is directed to Dr. 
Roenigk. Your study of liver biopsies from patients on 
etretinate did not have controls. Would you put in per- 
spective what you would predict would have happened 
in this group of patients if they were not treated? I 
realize that clinical investigation committees would 
probably not look favorably on doing serial liver biop- 
sies in a control group. 
H. H. Roenigk, Jr. ,  M.D.: You could consider that 
the patients erve as their own controls, and it is pro- 
spective in the sense that they do have pretreatment 
liver biopsies. We personally do have a vast experience 
with methotrexate, and there are many papers in the 
literature on liver biopsies done in psoriatic patients not 
treated with methotrexate. Variable changes are seen in 
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these patients, and I do not know that there is an answer 
to your question. I think that there are certain other 
toxic exposures that patients experience. People get 
hepatitis, people are exposed to alcohol, there is muscle 
damage, etc., all of which can affect the liver. For 
example, one of our patients went from fibrosis to cir- 
rhosis; we are fairly certain this was due to alcohol 
ingestion because he admitted that he was a heavy 
drinker and also was using some other nonapproved 
drugs. He has had Mallory bodies in the liver biopsy to 
support his. No one has taken the general population of 
psoriasis patients and followed them for 3 years with 
liver biopsies every year. I do not think that study will 
ever be done. 
J. G. Marks, Jr. ,  M.D.: What were the mor- 
phologic hanges in the liver in animals that were given 
the same dosage as would be given to humans? 
H. H. Roenigk, Jr. ,  M.D.: We have looked into 
this, but there is no animal model with methotrexate 
that produces liver damage similar to what is seen in 
humans. 
E. M. Farber, M.D.: There is the growing demand 
for retinoid therapy in psoriasis. Is there any experience 
with the use of isotretinoin in psoriasis? Does it work at 
all? This is important because if isotretinoin becomes 
available commercially soon, then of course there will 
be a large demand that it be used for treatment of 
psoriasis. What is the comparison of the two retinoids 
in the management of psoriasis? 
G. L, Peck, M.D.: Originally, isotretinoin was used 
in psoriasis by Runne et al (Arch Dermatol Forsch 
247:171, 1973.). They felt that it was not really of 
value, considering the side effects that were produced 
when it was used alone. In my series of eight patients, 
half improved and half did not. The question remains, 
though, once it is available by prescription whether it 
could be useful in a combination therapy program. 
E. M. Farber, M.D.: I am surprised that isotreti- 
noin has been dropped as a therapeutic agent for psori- 
asis with such alimited clinical testing period. Dr. Peck 
speaks of eight patients plus the studies by Dr. Orfanos. 
Has anyone else tried this? 
G. Plewig, M.D.: I can support Dr. Peck. Isotreti- 
noin, as a single agent, is much less effective than 
etretinate in controlling psoriasis. We do not use iso- 
tretinoin for the treatment of psoriasis, be it alone or in 
combination. All of the combination treatment sched- 
ules in Europe reported so far have involved the use of 
etretinate. Many combinations have been studied, In 
our department the use of the Goeckerman or the In- 
gram technics, as well as the short-term application of 
anthralin for 20 minutes, is being evaluated. Of course, 
we have combined etretinate with PUVA in certain 
instances. 
A. J .  Miller, M.B., B.S., M.R.C.P. :  Concerning 
unreported side effects with etretinate, I have had two 
patients reported o me who developed edema, one pe- 
ripheral edema, the other peripheral and pulmonary 
edema. Considering the number of patients who have 
been exposed to this drug in the United Kingdom in the 
last 2 years, this is not very common. It appeared to be 
a drug effect in that it disappeared upon cessation of 
treatment and returned on re-exposure to the drug. Fur- 
thermore, I have seen today for the first time, unbe- 
known to me, that this is also a feature of hypervita- 
minosis A. 
K. M. Halprin, M.D.: In terms of inhibition of 
spermatogenesis, are there data on how long this lasts. 
Are there any data to indicate that abnormal fetuses can 
result from the mating of a treated male animal with a 
normal female animal? 
D. B. Windhorst, M.D.: In more than sixty patients 
evaluated before and after treatment, we have no indi- 
cation that there is any effect on sperm motility or 
count. Therefore, in the human at the doses of isotreti- 
noin that we are giving, we find no evidence of any 
abnormality related to therapy. There are similar nega- 
tive data with etretinate therapy. The animal findings 
followed the administration of much larger doses. 
